91ÊÓƵרÇø

»å²¹²Ô²µ°ù²¹²Ô£¬²â²¹´Ç²õ³ó¾±²â´Ç³Ü²µ±ð³¾±ð¾±³¾±ð¾±£¬²â¾±²Ô¾±²¹²Ô²â³Ü²¹²Ô²â¾±³Ù¾±³ó³Ü²¹²Ô·É´ÇÂá¾±³¦¾±£¬°ù²¹²Ô²µ·É´Ç³¦³ó³Ü±ç³Ü±ô¾±³Ü»å²¹±ô¾±³Ü»å²¹£¬Âá¾±³Ü²µ±ð²Ô²µ³ó²¹´Ç±ô¾±²¹´Ç¡£³¦¾±³¦¾±³Ù±ð²Ô²µ³æ³Ü²Ô²õ³Ü¾±°ù²¹²Ô²õ³ó´Ç³Ü·É´Ç³¦³ó²¹²Ô²µ³æ¾±²¹²Ô²µ²õ¾±2»å±ð»å³ÜÂá¾±²¹·É²¹²Ô²µ²ú´Ç£¬»å²¹²ÔÂá¾±²¹²Ô²µ²õ³Ü·É±ð¾±²õ³ó¾±³ó±ð»å´Ç²Ô²µ´Ú²¹²Ô²µ·É±ð¾±²õ³ó¾±±ô¾±²¹²Ô²µ»å²¹»å¾±´Ú²¹²Ô²µ³Ù²¹¾±£¬²â±ð²µ´Ç³Ü°ù³Ü±ô¾±²¹´Ç²ú²¹²Ô±ç³Ü²¹²Ô»å²¹²õ³Ü²¹²Ô´Ú±ð²Ô²â¾±²ú±ð¾±²µ±ð²Ô²µ¡£

Èç(Ru)ºÎ(He)Çø(Qu)·Ö(Fen)·Ç(Fei)µä(Dian)ÐÍ(Xing)CMLÓë(Yu)Æä(Qi)Ëû(Ta)¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Ö³(Zhi)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)Ô­(Yuan)´´(Chuang)2020-09-12 17:53¡¤Ò½(Yi)Âö(Mai)ͨ(Tong)Ѫ(Xue)Òº(Ye)¿Æ(Ke)×÷(Zuo)Õß(Zhe)£ºÀ¶(Lan)¾¨(Jing)Ïþ(Xiao)»¢(Hu)±¾(Ben)ÎÄ(Wen)Ϊ(Wei)×÷(Zuo)Õß(Zhe)ÊÚ(Shou)Ȩ(Quan)Ò½(Yi)Âö(Mai)ͨ(Tong)·¢(Fa)²¼(Bu)£¬Î´(Wei)¾­(Jing)ÊÚ(Shou)Ȩ(Quan)Çë(Qing)Îð(Wu)ת(Zhuan)ÔØ(Zai)¡£·Ç(Fei)µä(Dian)ÐÍ(Xing)Âý(Man)ÐÔ(Xing)Ëè(Sui)ϵ(Xi)°×(Bai)Ѫ(Xue)²¡(Bing)(aCML)£¬BCR-ABL1(£­)£¬ÊÇ(Shi)Ò»(Yi)ÖÖ(Zhong)º±(Han)¼û(Jian)µÄ(De)Ѫ(Xue)Òº(Ye)¶ñ(E)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)£¬Êô(Shu)ÓÚ(Yu)WHO¹Ç(Gu)Ëè(Sui)Ö×(Zhong)Áö(Liu)·Ö(Fen)Àà(Lei)ÖÐ(Zhong)µÄ(De)¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Éú(Sheng)Òì(Yi)³£(Chang)/¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Ö³(Zhi)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)(MDS/MPN)¡£aCML×î(Zui)³õ(Chu)±»(Bei)Ãü(Ming)Ãû(Ming)Ϊ(Wei)¡°·Ç(Fei)µä(Dian)ÐÍ(Xing)¡±ÐÎ(Xing)ʽ(Shi)µÄ(De)Âý(Man)ÐÔ(Xing)Ëè(Sui)ϵ(Xi)°×(Bai)Ѫ(Xue)²¡(Bing)(CML)£¬¼¸(Ji)Ê®(Shi)Äê(Nian)À´(Lai)aCMLµÄ(De)Õï(Zhen)¶Ï(Duan)±ê(Biao)×¼(Zhun)·¢(Fa)Éú(Sheng)ÁË(Liao)ÏÔ(Xian)Öø(Zhu)±ä(Bian)»¯(Hua)¡£È»(Ran)¶ø(Er)£¬aCMLµÄ(De)Õï(Zhen)¶Ï(Duan)ȱ(Que)·¦(Fa)ÌØ(Te)Õ÷(Zheng)ÐÔ(Xing)£¬¶Ô(Dui)Æä(Qi)·Ö(Fen)×Ó(Zi)»ù(Ji)Òò(Yin)ͼ(Tu)Æ×(Pu)µÄ(De)ÈÕ(Ri)Òæ(Yi)ÁË(Liao)½â(Jie)ÓÐ(You)Öú(Zhu)ÓÚ(Yu)Çø(Qu)·Ö(Fen)aCMLÓë(Yu)Æä(Qi)Ëû(Ta)MDS/MPNºÍ(He)MPNs£¬ÒÔ(Yi)±ã(Bian)Ôç(Zao)ÆÚ(Qi)Æô(Qi)¶¯(Dong)ÖÎ(Zhi)ÁÆ(Liao)ºÍ(He)¸Ä(Gai)ÉÆ(Shan)Ô¤(Yu)ºó(Hou)¡£aCMLµÄ(De)ÁÙ(Lin)´²(Chuang)ºÍ(He)ÐÎ(Xing)̬(Tai)±í(Biao)ÐÍ(Xing)aCML»¼(Huan)Õß(Zhe)±í(Biao)ÏÖ(Xian)³ö(Chu)¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Éú(Sheng)ÌØ(Te)Õ÷(Zheng)£¬°ü(Bao)À¨(Kuo)°×(Bai)ϸ(Xi)°û(Bao)Ôö(Zeng)¶à(Duo)ºÍ(He)Æ¢(Pi)Ö×(Zhong)´ó(Da)£¬¿É(Ke)°é(Ban)ÓÐ(You)ƶ(Pin)Ѫ(Xue)ºÍ(He)Ѫ(Xue)С(Xiao)°å(Ban)¼õ(Jian)ÉÙ(Shao)¡£WBC¼Æ(Ji)Êý(Shu)¡Ý13¡Á109/L¡£Íâ(Wai)ÖÜ(Zhou)Ѫ(Xue)ÖÐ(Zhong)´æ(Cun)ÔÚ(Zai)ÖÁ(Zhi)ÉÙ(Shao)10%µÄ(De)δ(Wei)³É(Cheng)Êì(Shu)Á£(Li)ϸ(Xi)°û(Bao)£¨°ü(Bao)À¨(Kuo)Ôç(Zao)Ó×(You)Á£(Li)ϸ(Xi)°û(Bao)¡¢ÖÐ(Zhong)Ó×(You)Á£(Li)ϸ(Xi)°û(Bao)ºÍ(He)Íí(Wan)Ó×(You)Á£(Li)ϸ(Xi)°û(Bao)£©£¬ÒÔ(Yi)ÖØ(Zhong)¶È(Du)Á£(Li)ϸ(Xi)°û(Bao)Éú(Sheng)³É(Cheng)ÕÏ(Zhang)°­(Ai)Ϊ(Wei)ÌØ(Te)Õ÷(Zheng)¡£²»(Bu)´æ(Cun)ÔÚ(Zai)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)Ôö(Zeng)¶à(Duo)£¨Íâ(Wai)ÖÜ(Zhou)Ѫ(Xue)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)<Ѫ(Xue)Òº(Ye)°×(Bai)ϸ(Xi)°û(Bao)µÄ(De)10%£¬Ñª(Xue)Òº(Ye)¼Æ(Ji)Êý(Shu)< 1¡Á109/L£©Íâ(Wai)ÖÜ(Zhou)Ѫ(Xue)ÖÐ(Zhong)µÄ(De)ÊÈ(Shi)¼î(Jian)ÐÔ(Xing)Á£(Li)ϸ(Xi)°û(Bao)< 2%¡£¹Ç(Gu)Ëè(Sui)ºÍ(He)Íâ(Wai)ÖÜ(Zhou)Ѫ(Xue)ÖÐ(Zhong)Ô­(Yuan)ʼ(Shi)ϸ(Xi)°û(Bao)£¨°ü(Bao)À¨(Kuo)Ó×(You)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)£©< 20%¡£ÐÎ(Xing)̬(Tai)ѧ(Xue)ÉÏ(Shang)£¬aCMLÍâ(Wai)ÖÜ(Zhou)Ѫ(Xue)±í(Biao)ÏÖ(Xian)Ϊ(Wei)ÑÏ(Yan)ÖØ(Zhong)Á£(Li)ϸ(Xi)°û(Bao)Òì(Yi)ÐÍ(Xing)Ôö(Zeng)Éú(Sheng)¡£ÌØ(Te)Õ÷(Zheng)ÐÔ(Xing)±í(Biao)ÏÖ(Xian)°ü(Bao)À¨(Kuo)ÖÐ(Zhong)ÐÔ(Xing)Á£(Li)ϸ(Xi)°û(Bao)µÄ(De)Ⱦ(Ran)É«(Se)ÖÊ(Zhi)¹ý(Guo)¶È(Du)¾Û(Ju)¼¯(Ji)ÒÔ(Yi)¼°(Ji)ºË(He)·Ö(Fen)ÁÑ(Lie)Ïó(Xiang)Òì(Yi)³£(Chang)£¬Èç(Ru)ºË(He)µÍ(Di)·Ö(Fen)Ò¶(Ye)(¼Ù(Jia)Pelger-HuetºË(He))»ò(Huo)¶à(Duo)·Ö(Fen)Ò¶(Ye)¡£°û(Bao)½¬(Jiang)¿É(Ke)³Ê(Cheng)¿Å(Ke)Á£(Li)¼õ(Jian)ÉÙ(Shao)Éõ(Shen)ÖÁ(Zhi)Òì(Yi)³£(Chang)Ôö(Zeng)´ó(Da)¡£¹Ç(Gu)Ëè(Sui)ϸ(Xi)°û(Bao)¹ý(Guo)¶à(Duo)£¬ÒÔ(Yi)Á£(Li)ϸ(Xi)°û(Bao)Ϊ(Wei)Ö÷(Zhu)£¬³Ê(Cheng)Ã÷(Ming)ÏÔ(Xian)Òì(Yi)ÐÍ(Xing)Ôö(Zeng)Éú(Sheng)¡£°ë(Ban)Êý(Shu)ÒÔ(Yi)ÉÏ(Shang)²¡(Bing)Àý(Li)ÓÐ(You)ºì(Hong)ϵ(Xi)·¢(Fa)Óý(Yu)²»(Bu)Á¼(Liang)ºÍ(He)Ò»(Yi)¶¨(Ding)³Ì(Cheng)¶È(Du)µÄ(De)¾Þ(Ju)ºË(He)ϸ(Xi)°û(Bao)·¢(Fa)Óý(Yu)²»(Bu)Á¼(Liang)¡£´Ë(Ci)Íâ(Wai)£¬¿É(Ke)¼û(Jian)²»(Bu)ͬ(Tong)³Ì(Cheng)¶È(Du)µÄ(De)Íø(Wang)Ó²(Ying)µ°(Dan)°×(Bai)ÏË(Xian)ά(Wei)Ôö(Zeng)¼Ó(Jia)¡£WHO 2016Äê(Nian)Ìá(Ti)³ö(Chu)µÄ(De)aCMLÒÔ(Yi)¼°(Ji)¾ß(Ju)ÓÐ(You)Ïà(Xiang)ËÆ(Si)ÌØ(Te)Õ÷(Zheng)µÄ(De)Ëè(Sui)ϵ(Xi)Ö×(Zhong)Áö(Liu)Õï(Zhen)¶Ï(Duan)±ê(Biao)×¼(Zhun)×Ü(Zong)½á(Jie)¼û(Jian)ÏÂ(Xia)±í(Biao)¡£×¢(Zhu)£ºaCML£¬·Ç(Fei)µä(Dian)ÐÍ(Xing)Âý(Man)ÐÔ(Xing)Ëè(Sui)ÐÔ(Xing)°×(Bai)Ѫ(Xue)²¡(Bing)£»BM£¬¹Ç(Gu)Ëè(Sui)£»CMML£¬Âý(Man)ÐÔ(Xing)Á£(Li)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)°×(Bai)Ѫ(Xue)²¡(Bing)£»ET£¬Ô­(Yuan)·¢(Fa)ÐÔ(Xing)Ѫ(Xue)С(Xiao)°å(Ban)Ôö(Zeng)¶à(Duo)Ö¢(Zheng)£»MDS/MPN-RS-T£¬¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Éú(Sheng)Òì(Yi)³£(Chang)/¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Éú(Sheng)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)°é(Ban)»·(Huan)ÐÎ(Xing)Ìú(Tie)Á£(Li)Ó×(You)ϸ(Xi)°û(Bao)ºÍ(He)Ѫ(Xue)С(Xiao)°å(Ban)Ôö(Zeng)¶à(Duo)Ö¢(Zheng)£»MDS/MPN-U£¬¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Éú(Sheng)Òì(Yi)³£(Chang)/¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Éú(Sheng)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)£¬²»(Bu)¿É(Ke)·Ö(Fen)Àà(Lei)£»PV£¬Õæ(Zhen)ÐÔ(Xing)ºì(Hong)ϸ(Xi)°û(Bao)Ôö(Zeng)¶à(Duo)Ö¢(Zheng)£»PB£¬Íâ(Wai)ÖÜ(Zhou)Ѫ(Xue)¡£aCMLµÄ(De)ϸ(Xi)°û(Bao)ÒÅ(Yi)´«(Chuan)ѧ(Xue)ÌØ(Te)Õ÷(Zheng)¾¡(Jin)¹Ü(Guan)¸ù(Gen)¾Ý(Ju)¶¨(Ding)Òå(Yi)£¬aCMLȱ(Que)·¦(Fa)·Ñ(Fei)³Ç(Cheng)Ⱦ(Ran)É«(Se)Ìå(Ti)¼°(Ji)BCR-ABL1ÖØ(Zhong)ÅÅ(Pai)£¬µ«(Dan)Ô¼(Yue)Ò»(Yi)°ë(Ban)µÄ(De)aCML²¡(Bing)Àý(Li)´æ(Cun)ÔÚ(Zai)ϸ(Xi)°û(Bao)ÒÅ(Yi)´«(Chuan)ѧ(Xue)»û(Ji)±ä(Bian)£¬°ü(Bao)À¨(Kuo)8Èý(San)Ìå(Ti)¡¢YȾ(Ran)É«(Se)Ìå(Ti)ȱ(Que)ʧ(Shi)¡¢20ºÅ(Hao)Ⱦ(Ran)É«(Se)Ìå(Ti)³¤(Chang)±Û(Bi)²¿(Bu)·Ö(Fen)ȱ(Que)ʧ(Shi)(20q-)¡¢17ºÅ(Hao)µÈ(Deng)±Û(Bi)Ⱦ(Ran)É«(Se)Ìå(Ti)¡¢Éæ(She)¼°(Ji)12¡¢13¡¢14¡¢17ºÅ(Hao)Ⱦ(Ran)É«(Se)Ìå(Ti)µÄ(De)ȱ(Que)ʧ(Shi)ºÍ(He)¸´(Fu)ÔÓ(Za)ºË(He)ÐÍ(Xing)¡£È»(Ran)¶ø(Er)Õâ(Zhe)Щ(Xie)ϸ(Xi)°û(Bao)ÒÅ(Yi)´«(Chuan)ѧ(Xue)Òì(Yi)³£(Chang)¾ù(Jun)·Ç(Fei)aCMLËù(Suo)ÌØ(Te)ÓÐ(You)£¬ÇÒ(Qie)Ïà(Xiang)µ±(Dang)¶à(Duo)µÄ(De)²¡(Bing)Àý(Li)£¨¸ß(Gao)´ï(Da)80%£©¿É(Ke)¾ß(Ju)ÓÐ(You)Õý(Zheng)³£(Chang)µÄ(De)ºË(He)ÐÍ(Xing)¡£aCMLµÄ(De)¸´(Fu)·¢(Fa)ÐÔ(Xing)»ù(Ji)Òò(Yin)Í»(Tu)±ä(Bian)aCMLÖÐ(Zhong)×î(Zui)³£(Chang)¼û(Jian)µÄ(De)Í»(Tu)±ä(Bian)»ù(Ji)Òò(Yin)ÊÇ(Shi)ASXL1¡¢NRAS¡¢SETBP1¡¢SRSF2ºÍ(He)TET2¡£×î(Zui)½ü(Jin)ÑÐ(Yan)¾¿(Jiu)±í(Biao)Ã÷(Ming)£¬69%µÄ(De)aCML²¡(Bing)Àý(Li)ÔÚ(Zai)±í(Biao)¹Û(Guan)ÒÅ(Yi)´«(Chuan)ÐÞ(Xiu)ÊÎ(Shi)»ù(Ji)Òò(Yin)TET2¡¢IDH1/2¡¢DNMT3A¡¢EZH2ºÍ(He)/»ò(Huo)ASXL1ÖÐ(Zhong)Я(Xie)´ø(Dai)ÖÁ(Zhi)ÉÙ(Shao)Ò»(Yi)ÖÖ(Zhong)Í»(Tu)±ä(Bian)¡£Í¼(Tu)1×Ü(Zong)½á(Jie)ÁË(Liao)aCMLÖÐ(Zhong)×î(Zui)³£(Chang)¼û(Jian)µÄ(De)Í»(Tu)±ä(Bian)¡£Èç(Ru)ºÎ(He)Õï(Zhen)¶Ï(Duan)aCMLÕï(Zhen)¶Ï(Duan)aCMLÓ¦(Ying)»ù(Ji)ÓÚ(Yu)ʶ(Shi)±ð(Bie)Æä(Qi)ÌØ(Te)Õ÷(Zheng)ÐÔ(Xing)µÄ(De)ÐÎ(Xing)̬(Tai)ѧ(Xue)¡¢Êµ(Shi)Ñé(Yan)ÊÒ(Shi)ºÍ(He)ÒÅ(Yi)´«(Chuan)ѧ(Xue)ÌØ(Te)Õ÷(Zheng)£¬ÅÅ(Pai)³ý(Chu)¾ß(Ju)ÓÐ(You)Ã÷(Ming)È·(Que)ÒÅ(Yi)´«(Chuan)ѧ(Xue)¸Ä(Gai)±ä(Bian)µÄ(De)Æä(Qi)Ëû(Ta)Ëè(Sui)ϵ(Xi)¶ñ(E)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)¡£³õ(Chu)²½(Bu)¼ì(Jian)²é(Cha)Ó¦(Ying)²à(Ce)ÖØ(Zhong)ÓÚ(Yu)ÅÅ(Pai)³ý(Chu)BCR-ABL1ÈÚ(Rong)ºÏ(He)£¬¸ù(Gen)¾Ý(Ju)¶¨(Ding)Òå(Yi)£¬CML±Ø(Bi)È»(Ran)´æ(Cun)ÔÚ(Zai)BCR-ABL1ÈÚ(Rong)ºÏ(He)£¬¶ø(Er)aCMLÖÐ(Zhong)ÎÞ(Wu)´Ë(Ci)ÏÖ(Xian)Ïó(Xiang)¡£»¹(Huan)Ó¦(Ying)ÅÅ(Pai)³ý(Chu)Æä(Qi)Ëû(Ta)²¡(Bing)Àí(Li)ÐÔ(Xing)»ù(Ji)Òò(Yin)Í»(Tu)±ä(Bian)£¬Èç(Ru)PDGFRA¡¢PDGFRB¡¢FGFR1£¬»ò(Huo)PCM1-JAK2ÈÚ(Rong)ºÏ(He)¡£¼ø(Jian)ÓÚ(Yu)Õâ(Zhe)Щ(Xie)ÖØ(Zhong)ÅÅ(Pai)¿É(Ke)ÄÜ(Neng)´æ(Cun)ÔÚ(Zai)ÒÅ(Yi)´«(Chuan)ѧ(Xue)Òþ(Yin)ÃØ(Mi)£¬³ý(Chu)ÁË(Liao)ºË(He)ÐÍ(Xing)·Ö(Fen)Îö(Xi)£¬ÔÚ(Zai)È·(Que)¶¨(Ding)aCMLÕï(Zhen)¶Ï(Duan)Ö®(Zhi)Ç°(Qian)£¬Ó¦(Ying)¿¼(Kao)ÂÇ(Lv)FISH¼ì(Jian)²â(Ce)»ò(Huo)RNA-²â(Ce)Ðò(Xu)À´(Lai)ÅÅ(Pai)³ý(Chu)ÉÏ(Shang)Êö(Shu)Çé(Qing)¿ö(Kuang)¡£PDGFRBÖØ(Zhong)ÅÅ(Pai)µÄ(De)Ëè(Sui)ϵ(Xi)Ö×(Zhong)Áö(Liu)»¼(Huan)Õß(Zhe)¿É(Ke)±í(Biao)ÏÖ(Xian)Ϊ(Wei)MDS/MPNÑù(Yang)±í(Biao)ÐÍ(Xing)£¬ÐÎ(Xing)̬(Tai)ѧ(Xue)ÌØ(Te)Õ÷(Zheng)Óë(Yu)aCMLÏà(Xiang)ËÆ(Si)¡£ÏÖ(Xian)ÒÑ(Yi)Òâ(Yi)ʶ(Shi)µ½(Dao)£¬PDGFRBÖØ(Zhong)ÅÅ(Pai)µÄ(De)Ëè(Sui)ϵ(Xi)Ö×(Zhong)Áö(Liu)¾ß(Ju)ÓÐ(You)·Ç(Fei)³£(Chang)¹ã(Guang)·º(Fan)µÄ(De)±í(Biao)ÐÍ(Xing)£¬²¢(Bing)²»(Bu)¾Ö(Ju)ÏÞ(Xian)ÓÚ(Yu)°é(Ban)ÊÈ(Shi)Ëá(Suan)ÐÔ(Xing)Á£(Li)ϸ(Xi)°û(Bao)Ôö(Zeng)¶à(Duo)ÌØ(Te)Õ÷(Zheng)µÄ(De)CMML¡£Ê¶(Shi)±ð(Bie)ÖØ(Zhong)ÅÅ(Pai)£¨Èç(Ru)PDGFRB/PDGFRA£©ÖÁ(Zhi)¹Ø(Guan)ÖØ(Zhong)Òª(Yao)£¬Òò(Yin)Ϊ(Wei)Óë(Yu)aCMLÏà(Xiang)±È(Bi)£¬¾ß(Ju)ÓÐ(You)Õâ(Zhe)Àà(Lei)ÌØ(Te)Õ÷(Zheng)µÄ(De)¼²(Ji)²¡(Bing)¶Ô(Dui)ÀÒ(Lao)°±(An)Ëá(Suan)¼¤(Ji)ø(Mei)ÒÖ(Yi)ÖÆ(Zhi)¼Á(Ji)£¨ÒÁ(Yi)Âí(Ma)Ìæ(Ti)Äá(Ni)£©µÄ(De)Ãô(Min)¸Ð(Gan)ÐÔ(Xing)¸ß(Gao)£¬Ô¤(Yu)ºó(Hou)½Ï(Jiao)ºÃ(Hao)¡£Çø(Qu)·Ö(Fen)aCMLÓë(Yu)ij(Mou)Щ(Xie)BCR-ABL1£¨-£©µÄ(De)MPNs £¨CNL£¬Ô­(Yuan)·¢(Fa)ÐÔ(Xing)¹Ç(Gu)Ëè(Sui)ÏË(Xian)ά(Wei)»¯(Hua)[PMF]£©ºÍ(He)MDS/MPN£¨CMMLºÍ(He)MDS/MPN-U£©¾ß(Ju)ÓÐ(You)Ìô(Tiao)Õ½(Zhan)ÐÔ(Xing)¡£MPN¼È(Ji)Íù(Wang)Ê·(Shi)¿É(Ke)ÅÅ(Pai)³ý(Chu)aCMLµÄ(De)Õï(Zhen)¶Ï(Duan)¡£¹Ç(Gu)Ëè(Sui)»î(Huo)¼ì(Jian)·¢(Fa)ÏÖ(Xian)µä(Dian)ÐÍ(Xing)µÄ(De)MPNÐÎ(Xing)̬(Tai)ѧ(Xue)½á(Jie)¹û(Guo)£¨ÓÈ(You)Æä(Qi)ÊÇ(Shi)ÔÚ(Zai)û(Mei)ÓÐ(You)ÏÔ(Xian)Öø(Zhu)Á£(Li)ϸ(Xi)°û(Bao)·¢(Fa)Óý(Yu)²»(Bu)Á¼(Liang)µÄ(De)Çé(Qing)¿ö(Kuang)ÏÂ(Xia)£©ºÍ(He)MPNÏà(Xiang)¹Ø(Guan)Í»(Tu)±ä(Bian)£¨ÔÚ(Zai)JAK2¡¢CALR»ò(Huo)MPLÖÐ(Zhong)£©Ê±(Shi)£¬²»(Bu)Çã(Qing)Ïò(Xiang)aCML£¬Ìá(Ti)ʾ(Shi)PMF¡¢Õæ(Zhen)ÐÔ(Xing)ºì(Hong)ϸ(Xi)°û(Bao)Ôö(Zeng)¶à(Duo)Ö¢(Zheng)(PV)»ò(Huo)Ô­(Yuan)·¢(Fa)ÐÔ(Xing)Ѫ(Xue)С(Xiao)°å(Ban)Ôö(Zeng)¶à(Duo)Ö¢(Zheng)(ET)¡£Ìá(Ti)ʾ(Shi)ÐÔ(Xing)µÄ(De)Í»(Tu)±ä(Bian)ÌØ(Te)Õ÷(Zheng)£¨Èç(Ru)SETBP1/ETNK1Í»(Tu)±ä(Bian)£©ÇÒ(Qie)¾ß(Ju)ÓÐ(You)·û(Fu)ºÏ(He)Õï(Zhen)¶Ï(Duan)±ê(Biao)×¼(Zhun)µÄ(De)ÌØ(Te)Õ÷(Zheng)ÓÐ(You)Öú(Zhu)ÓÚ(Yu)Ö¤(Zheng)ʵ(Shi)aCML¡£Íâ(Wai)ÖÜ(Zhou)Ѫ(Xue)ÖÐ(Zhong)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)µÄ(De)°Ù(Bai)·Ö(Fen)±È(Bi)ÊÇ(Shi)Çø(Qu)·Ö(Fen)aCMLºÍ(He)CMMLµÄ(De)ÖØ(Zhong)Òª(Yao)ÌØ(Te)Õ÷(Zheng)£¬ÔÚ(Zai)aCMLÖÐ(Zhong)ʼ(Shi)ÖÕ(Zhong)µÍ(Di)ÓÚ(Yu)10%£¨ºÜ(Hen)ÉÙ(Shao)>2%£©¡£Ï¸(Xi)°û(Bao)»¯(Hua)ѧ(Xue)Ⱦ(Ran)É«(Se)£¬Èç(Ru)·Ç(Fei)ÌØ(Te)Òì(Yi)ÐÔ(Xing)õ¥(Zuo)ø(Mei)(NSE)ÓÐ(You)Öú(Zhu)ÓÚ(Yu)ÔÚ(Zai)ÒÉ(Yi)ÄÑ(Nan)²¡(Bing)Àý(Li)ÖÐ(Zhong)¼ì(Jian)²â(Ce)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)¡£Áí(Ling)Ò»(Yi)¸ö(Ge)¸ü(Geng)Ö÷(Zhu)¹Û(Guan)µÄ(De)ÐÎ(Xing)̬(Tai)ѧ(Xue)Çø(Qu)±ð(Bie)ÊÇ(Shi)aCML´æ(Cun)ÔÚ(Zai)¸ü(Geng)ÑÏ(Yan)ÖØ(Zhong)µÄ(De)Á£(Li)ϸ(Xi)°û(Bao)·¢(Fa)Óý(Yu)²»(Bu)Á¼(Liang)£¬¾¡(Jin)¹Ü(Guan)ȱ(Que)·¦(Fa)ÆÀ(Ping)¹À(Gu)·¢(Fa)Óý(Yu)²»(Bu)Á¼(Liang)ÑÏ(Yan)ÖØ(Zhong)³Ì(Cheng)¶È(Du)µÄ(De)¾ß(Ju)Ìå(Ti)Ö¸(Zhi)ÄÏ(Nan)¡£Ðè(Xu)Òª(Yao)½ø(Jin)ÐÐ(Xing)Ìú(Tie)Ⱦ(Ran)É«(Se)ÒÔ(Yi)ÅÅ(Pai)³ý(Chu)°é(Ban)ÓÐ(You)»·(Huan)ÐÎ(Xing)Ìú(Tie)Á£(Li)Ó×(You)ϸ(Xi)°û(Bao)ºÍ(He)Ѫ(Xue)С(Xiao)°å(Ban)Ôö(Zeng)¶à(Duo)µÄ(De)MDS/MPN-RS-T¡£ÔÚ(Zai)ÒÔ(Yi)Ôö(Zeng)Ö³(Zhi)ÌØ(Te)Õ÷(Zheng)Ϊ(Wei)Ö÷(Zhu)£¬ÇÒ(Qie)ÒÔ(Yi)ÖÐ(Zhong)ÐÔ(Xing)Á£(Li)ϸ(Xi)°û(Bao)Ϊ(Wei)Ö÷(Zhu)µÄ(De)»¼(Huan)Õß(Zhe)ÖÐ(Zhong)£¬CSF3RÍ»(Tu)±ä(Bian)Ó¦(Ying)Ç¿(Qiang)ÁÒ(Lie)Ìá(Ti)ʾ(Shi)CNL¡£Çø(Qu)·Ö(Fen)aCMLÓë(Yu)MDS/MPN-U½Ï(Jiao)Ϊ(Wei)À§(Kun)ÄÑ(Nan)¡£aCML»¼(Huan)Õß(Zhe)µÄ(De)ÖÐ(Zhong)λ(Wei)WBC¼Æ(Ji)Êý(Shu)ÏÔ(Xian)Öø(Zhu)Éý(Sheng)¸ß(Gao)£¬µ«(Dan)·Ç(Fei)¾ø(Jue)¶Ô(Dui)ÌØ(Te)Õ÷(Zheng)¡£³Ö(Chi)Ðø(Xu)ÐÔ(Xing)µ¥(Dan)ºË(He)ϸ(Xi)°û(Bao)Ôö(Zeng)¶à(Duo)Ìá(Ti)ʾ(Shi)CMML¡£TET2+SRSF2Í»(Tu)±ä(Bian)¶Ô(Dui)CMML¾ß(Ju)ÓÐ(You)Ïà(Xiang)¶Ô(Dui)ÌØ(Te)Òì(Yi)ÐÔ(Xing)£¬¾¡(Jin)¹Ü(Guan)Á½(Liang)Õß(Zhe)ÔÚ(Zai)aCMLÖÐ(Zhong)¾ù(Jun)¿É(Ke)¼û(Jian)¡£Ò»(Yi)ÖÖ(Zhong)ÐÂ(Xin)µÄ(De)aCMLÕï(Zhen)¶Ï(Duan)Á÷(Liu)³Ì(Cheng)С(Xiao)½á(Jie)ÓÉ(You)ÓÚ(Yu)·¢(Fa)²¡(Bing)ÂÊ(Lv)µÍ(Di)¡¢Õï(Zhen)¶Ï(Duan)±ê(Biao)×¼(Zhun)²»(Bu)¶Ï(Duan)¸ü(Geng)ÐÂ(Xin)ºÍ(He)ȱ(Que)·¦(Fa)·Ö(Fen)×Ó(Zi)ÒÅ(Yi)´«(Chuan)ѧ(Xue)µÄ(De)Àí(Li)½â(Jie)£¬·Ç(Fei)µä(Dian)ÐÍ(Xing)Âý(Man)ÐÔ(Xing)Ëè(Sui)ϵ(Xi)°×(Bai)Ѫ(Xue)²¡(Bing)Ò»(Yi)Ö±(Zhi)ÊÇ(Shi)Ò»(Yi)ÖÖ(Zhong)ÄÑ(Nan)ÒÔ(Yi)Õï(Zhen)¶Ï(Duan)µÄ(De)MDS/MPN¡£Ëæ(Sui)×Å(Zhuo)¶Ô(Dui)»ù(Ji)Òò(Yin)×é(Zu)´ó(Da)Êý(Shu)¾Ý(Ju)µÄ(De)²»(Bu)¶Ï(Duan)ÍÚ(Wa)¾ò(Jue)£¬ÒÑ(Yi)·¢(Fa)ÏÖ(Xian)SETBP1ºÍ(He)ETNK1µÄ(De)·´(Fan)¸´(Fu)Í»(Tu)±ä(Bian)¶Ô(Dui)aCMLÓÐ(You)Ìá(Ti)ʾ(Shi)×÷(Zuo)ÓÃ(Yong)£¬¿É(Ke)ÒÔ(Yi)½á(Jie)ºÏ(He)ʵ(Shi)Ñé(Yan)ÊÒ(Shi)ºÍ(He)ÐÎ(Xing)̬(Tai)ѧ(Xue)½á(Jie)¹û(Guo)À´(Lai)Çø(Qu)·Ö(Fen)aCMLºÍ(He)Æä(Qi)Ëû(Ta)·Ñ(Fei)³Ç(Cheng)Òõ(Yin)ÐÔ(Xing)¹Ç(Gu)Ëè(Sui)Ôö(Zeng)Ö³(Zhi)ÐÔ(Xing)Ö×(Zhong)Áö(Liu)¡£È»(Ran)¶ø(Er)Í»(Tu)±ä(Bian)µÄ(De)ͬ(Tong)ʱ(Shi)·¢(Fa)Éú(Sheng)ÊÇ(Shi)·ñ(Fou)»á(Hui)¸Ä(Gai)±ä(Bian)aCMLµÄ(De)¼²(Ji)²¡(Bing)±í(Biao)ÐÍ(Xing)ºÍ(He)ÖÎ(Zhi)ÁÆ(Liao)·´(Fan)Ó¦(Ying)ÉÐ(Shang)²»(Bu)Ã÷(Ming)È·(Que)¡£²Î(Can)¿¼(Kao)ÎÄ(Wen)Ï×(Xian)£º1. Orazi A, Bennett JM, Bain BJ, et al. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, et al, editors. WHO Classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2017. pp. 87¨C89.2. Kantarjian HM, Keating MJ, Walters RS, et al. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer 1986; 58:2023¨C2030.3. Kurzrock R, Bueso-Ramos CE, Kantarjian H, et al. BCR rearrangement-negative chronic myelogenous leukemia revisited. J Clin Oncol 2001; 19:2915¨C2926.4. Giri S, Pathak R, Martin MG, Bhatt VR. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database. Ther Adv Hematol 2015; 6:308¨C312.5. Sadigh S, Hasserjian RP, Hobbs G. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms. Curr Opin Hematol. 2020;27(2):122-127.6. Itonaga H, Ota S, Ikeda T, et al. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: a retrospective nationwide study in Japan. Leuk Res 2018; 75:50¨C57.7. Meggendorfer M, Haferlach T, Alpermann T, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica 2014; 99:e246.8. Wang SA, Hasserjian RP, Fox PS, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 2014; 123:2645 -2651.9. Patnaik MM, Barraco D, Lasho TL, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol 2017; 92:542¨C548.10. Schwartz LC, Mascarenhas J. Current and evolving understanding of atypical chronic myeloid leukemia. Blood Rev 2019; 33:74¨C81.11. Faisal M, Stark H, Busche G, € et al. Comprehensive mutation profiling and mRNA expression analysis in atypical chronic myeloid leukemia in comparison with chronic myelomonocytic leukemia. Cancer Med 2019; 8:742¨C750.12. Zhang H, Wilmot B, Bottomly D, et al. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood 2019; 134:867¨C879.13. Hasserjian RP. Illuminating neutrophilic myeloid neoplasms. Blood 2019; 134:846¨C848.14. Steer EJ, Cross NC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113¨C122.15. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood 2014; 123:3574¨C3577.16. Meggendorfer M, Roller A, Haferlach T, et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080¨C3088.

²õ²¹²ÔÂá¾±²¹³ú³Ü´Ç²â¾±Âá¾±²Ô²µ³¦³ó³Ü±ô²¹¾±£¬³ó±ð±ô¾±²Ô³ú³ó¾±³æ¾±²¹´Ç±ô²¹¾±²õ³ó²¹²Ô²µ²â¾±£¬³ú³ó³Ü´Ç°ù±ð²Ô±ç³Ü³ú³Ü´Ç³ó²¹´Ç³ú³Ü´Ç»å²¹¾±£¬³æ³Ü±ô¾±²¹´Ç±ð°ù²ú²¹¾±±ô¾±²¹²Ô²µ´Ú²¹²õ´Ç²Ô²µ³¦²¹¾±²ú²¹¡£

Åà(±Ê±ð¾±)Ñø(³Û²¹²Ô²µ)»ù(´³¾±)ÖÐ(´Ü³ó´Ç²Ô²µ)£¬Æ»(±Ê¾±²Ô²µ)¹û(³Ò³Ü´Ç)¸¯(¹ó³Ü)ÀÃ(³¢²¹²Ô)²¿(µþ³Ü)·Ö(¹ó±ð²Ô)µÄ(¶Ù±ð)¾ú(´³³Ü²Ô)Ë¿(³§¾±)Éú(³§³ó±ð²Ô²µ)³¤(°ä³ó²¹²Ô²µ)Á¼(³¢¾±²¹²Ô²µ)ºÃ(±á²¹´Ç)¡£ÊÜ(³§³ó´Ç³Ü)·Ã(¹ó²¹²Ô²µ)Õß(´Ü³ó±ð)¹©(³Ò´Ç²Ô²µ)ͼ(°Õ³Ü)

vivo£ºÌìÆøApp¡úÉèÖáúµØÕðÔ¤¾¯¡úÆôÓõØÕðÔ¤¾¯·þÎñÊ×·¢2024-07-11 04:30¡¤ÄÁͯÓéÂÛ´©Ô½֮ũ¸¾ÄÑΪ³åС˵Ãâ·ÑÔĶÁ-ÆðµãÖÐÎÄÍø

×øÁËÊ®¼¸Õ¾ÎÒÃǾ͵½ÁËÃÀÀöµÄó»Ô°

ÉùÃ÷£º¸ÃÎĹ۵ã½ö´ú±í×÷Õß±¾ÈË£¬ËѺüºÅϵÐÅÏ¢·¢²¼Æ½Ì¨£¬ËѺü½öÌṩÐÅÏ¢´æ´¢¿Õ¼ä·þÎñ¡£